- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02578563
Prospective Diabetes Registry of Patients With Type 2 Diabetes Mellitus on SGLT 2 Inhibitor Therapy in Singapore
SGLT2 Inhibitor Registry in Singapore
To evaluate clinical effectiveness and safety of Singaporean Type 2 Diabetes mellitus patients administered SGLT 2 inhibitor monotherapy or in combination with other commonly used hypoglycaemic drugs in real life clinical settings.
To evaluate real life clinical effectiveness and safety of Sodium-Glucose Co-Transporter inhibitor- 2 in Singaporean Type 2 diabetes mellitus patients treated on an outpatient basis in clinical practice setting. The study would also assess treatment patterns with SGLT2 inhibitor patient relevant outcomes in whole population as well as pre identified patient subgroups.
Primary analysis to be done at 1 year and extended analysis at 2 years.
Descripción general del estudio
Estado
Condiciones
Descripción detallada
T2DM is associated with overweight/obesity and high fasting plasma glucose (FPG) in White patients, whereas Asian patients are more predisposed to high abdominal fat distribution and high postprandial glucose (PPG) levels, thought to contribute1-4. In response to identical meals, Asian subjects exhibit greater glycemic response than do White subjects4,5. According to the Diabetic Society of Singapore, one out of nine people aged 18 to 69 has diabetes, that's about 11.3% of the population or more than 400,000 people & this is expected to rise with the increasing prevalence of a sedentary lifestyle and high-calorie dietary intake.
SGLT2 inhibitors offers a novel insulin-independent approach to lowering hyperglycaemia and improving metabolic control of type 2 diabetes: they reduce renal glucose reabsorption by inhibition of SGLT2 transporters in the proximal tubule of the kidney, resulting in urinary glucose excretion. Since SGLT2 inhibition is independent of β-cell function or insulin sensitivity, this treatment approach could have applications throughout the natural history of diabetes.6
The reductions in fasting plasma glucose concentration and bodyweight during the treatment with the SGLT2 i, are sustained. Early weight loss, is partly due to a mild osmotic diuresis caused by SGLT2 I, however, the gradual progressive reduction in bodyweight thereafter, with decreased waist circumference, is consistent with a reduction of fat mass. This reduction is potentially attributable to the loss of excess energy through glucose excretion in the urine, an effect supported by the increased urinary glucose/creatinine ratio in patients assigned to SGLT2i.6
Many trials shows that SGLT2 i can improve glycaemic control in patients who have inadequate control with metformin. The drug acts independently of insulin, lowers weight, and is not associated with risk of hypoglycaemia. Safety and tolerability of the drugs were also confirmed. Therefore, addition of SGLT2i to metformin provides a new therapeutic option for treatment of type 2 diabetes.6
Data collection will be done by AZ medical personnel or Pharmacy interns, it will be a paper data collection and will be handed over to the CRO company for data entry & analysis..Data analysis will be done by an independent CRO company namely BioQuest Solutions.
Tipo de estudio
Inscripción (Actual)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Singapore, Singapur
- Research Site
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
Patients should meet all of the following criteria at Day 0:
- Outpatient equal to or more than 18 years of age
- Diagnosed as T2DM and treated with antidiabetic medicines at least 3 months and suitable for SGLT2 inhibitor as current treatment judged by PI with HbA1c > 7.0 %
- Will provide completed and signed written informed consents Each participating investigator, will be asked to recruit a fixed number of patients ranging from 10 to 40 depending on site specificities.
Exclusion Criteria:
Patients, with the following criteria will be excluded at Day 0:
- Hypersensitivity to any SGLT2 inhibitor or any of the components in the formulation
- Patients with Type 1 diabetes
- Female patients with gestational diabetes during pregnancy
- Female patients who are pregnant, intending to become pregnant or breastfeeding
- Severe medical condition(s) that in the view of the investigator prohibits participation in the study e.g. cancer, end stage liver disease, end stage renal failure (non-diabetes related)
- Use of other investigational drugs at the time of enrolment
- Renal Function: <30ml/min/1.73m2
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: Solo caso
- Perspectivas temporales: Futuro
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from baseline in the HbA1c level after 1 year
Periodo de tiempo: baseline to 1 year
|
to assess whether the therapy initiated with SGLT2 inhibitors at baseline is able to reduce the HbA1c after 1 year.
|
baseline to 1 year
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change from baseline in FPG level at 6months
Periodo de tiempo: Blood samples are collected pre-dose, 6 months post-dose
|
By assessment of the other lipid level reduction from baseline lab value to the last lab value
|
Blood samples are collected pre-dose, 6 months post-dose
|
Change from baseline in FPG level at 12months
Periodo de tiempo: Blood samples are collected pre-dose, 12 months post-dose
|
By assessment of the other lipid level reduction from baseline lab value to the last lab value
|
Blood samples are collected pre-dose, 12 months post-dose
|
Change from baseline in weight at 6months
Periodo de tiempo: weight is measured pre-dose, 6 months post-dose
|
By assessment of the other weight reduction from baseline value to the last value
|
weight is measured pre-dose, 6 months post-dose
|
Change from baseline in weight at 12 months
Periodo de tiempo: weight is measured pre-dose, 12 months post-dose
|
By assessment of the other weight reduction from baseline value to the last value
|
weight is measured pre-dose, 12 months post-dose
|
Change from baseline in BP at 6 months
Periodo de tiempo: BP is measured pre-dose, 6 months post-dose
|
By assessment of the other BP reduction from baseline value to the last value
|
BP is measured pre-dose, 6 months post-dose
|
Change from baseline in BP at 12 months
Periodo de tiempo: BP is measured pre-dose, 12 months post-dose
|
By assessment of the other BP reduction from baseline value to the last value
|
BP is measured pre-dose, 12 months post-dose
|
Change from baseline in Lipids at 6 months
Periodo de tiempo: Blood samples are collected pre-dose, 6 months post-dose
|
By assessment of the other lipid level reduction from baseline lab value to the last lab value
|
Blood samples are collected pre-dose, 6 months post-dose
|
Change from baseline in Lipids at 12 months
Periodo de tiempo: Blood samples are collected pre-dose, 12 months post-dose
|
By assessment of the other lipid level reduction from baseline lab value to the last lab value
|
Blood samples are collected pre-dose, 12 months post-dose
|
Change from baseline in Waist circumference at 6 months
Periodo de tiempo: waist circumference is measured pre-dose, 6 months post-dose
|
By assessment of the other waist circumference reduction from baseline value to the last value
|
waist circumference is measured pre-dose, 6 months post-dose
|
Change from baseline in Waist circumference at 12 months
Periodo de tiempo: waist circumference is measured pre-dose, 12 months post-dose
|
By assessment of the other waist circumference reduction from baseline value to the last value
|
waist circumference is measured pre-dose, 12 months post-dose
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Publicaciones Generales
- REFERENCES 1. Wang JS, et al. Diabetes Metab Res Rev. 2011;27:79-84 2. Bonora E, et al. Diabetes Care. 2001;24:2023-2029 3. Peter R, et al. Diabet Med. 2006;23:990-995 4. Venn BS, et al. Diabet Med. 2010;27:1205-1208 5. Henry CJ, et al. Br J Nutr. 2008;99:840-845 6. Bailey CJ, et al. Lancet. 2010;375:2223-33
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- D1843R00258
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Diabetes mellitus
-
Meir Medical CenterTerminadoDiabetes mellitus tipo 2 | Diabetes Mellitus, No Insulino Dependiente | Diabetes Mellitus, sobre Tratamiento Hipoglucemiante Oral | Diabetes mellitus tipo adultoIsrael
-
Medical College of WisconsinMedical University of South CarolinaTerminadoDiabetes mellitus | Diabetes mellitus tipo 2 | Diabetes mellitus de inicio en adultos | Diabetes mellitus no insulinodependiente | Diabetes mellitus no insulinodependiente, tipo IIEstados Unidos
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.TerminadoDiabetes Mellitus, Tipo 1 | Diabetes tipo 1 | Diabetes tipo 1 | Diabetes mellitus tipo 1 | Diabetes autoinmune | Diabetes Mellitus, Insulino-Dependiente | Diabetes de inicio juvenil | Diabetes Autoinmune | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | Diabetes Mellitus... y otras condicionesEstados Unidos
-
SanofiTerminadoDiabetes Mellitus Tipo 1-Diabetes Mellitus Tipo 2Hungría, Federación Rusa, Alemania, Polonia, Japón, Estados Unidos, Finlandia
-
Medical College of WisconsinMedical University of South Carolina; National Institute of Diabetes and Digestive...Activo, no reclutandoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Medical College of WisconsinNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
Guang NingReclutamientoDiabetes mellitus tipo 2 | Diabetes mellitus tipo 1 | Diabetes monogenética | Diabetes pancreatogénica | Diabetes mellitus inducida por fármacos | Otras formas de diabetes mellitusPorcelana
-
Hoffmann-La RocheRoche DiagnosticsTerminadoDiabetes Mellitus Tipo 2, Diabetes Mellitus Tipo 1Alemania
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)TerminadoDiabetes Mellitus, Tipo 2 | Diabetes Mellitus, Tipo II | Diabetes mellitus, inicio en adultos | Diabetes mellitus, no insulinodependiente | Diabetes Mellitus, No Insulino DependienteEstados Unidos
-
University of California, San FranciscoJuvenile Diabetes Research FoundationTerminadoDiabetes mellitus tipo 1 | Diabetes Mellitus, Tipo I | Diabetes mellitus insulinodependiente 1 | Diabetes Mellitus, Insulino-Dependiente, 1 | IDDMEstados Unidos, Australia